The list price for Moxetumomab pasudotox-tdfk (Moxeza) is $37,500 per vial [1]. The recommended dosage is 1 mg/kg administered intravenously on days 1, 8, and 15 of each cycle for up to 8 cycles [2]. A typical patient might require multiple vials per dose, depending on their weight.
How much does a full course of Moxeza treatment cost?
The total cost of a full course of Moxeza treatment can be substantial, as it involves multiple doses over several weeks [2]. For example, a patient weighing 70 kg would require 70 mg per dose. If each vial contains a specific amount (information not provided in the source), the number of vials needed per dose would vary. Multiplying this by the number of doses in a full treatment course (up to 8 cycles, with doses on days 1, 8, and 15 of each cycle) would determine the overall expense [2].
What is the approved use for Moxeza?
Moxeza is approved for adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies [2][3]. It is also indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have received at least two prior systemic therapies [2][3].
How does Moxeza work?
Moxeza is a CD22-directed antibody and DNA damaging agent [2]. It targets CD22, a protein found on B cells, and delivers a cytotoxic agent directly to these cells, leading to their death [2].
What are the side effects of Moxeza?
Common side effects of Moxeza include decreased white blood cell count, nausea, fatigue, diarrhea, rash, and increased liver enzymes [2]. A serious risk is capillary leak syndrome, which can be life-threatening and may require hospitalization [2]. Patients should be monitored closely for signs of this condition [2].
Who manufactures Moxeza?
Moxeza is manufactured by AstraZeneca [1].